Finance

Lists
4151:TYO
Kyowa Kirin Co Ltd
2 544,00 JP¥
-0,90%
(-23,00) 1D
20-ноя., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4151...
Open
2 524 JP¥
High
2 574 JP¥
Low
2 516 JP¥
Mkt. cap
1,34 трлн
Avg. vol.
1,81 млн
Volume
1,13 млн
Dividend
2,63%
Quarterly dividend
17 JP¥
Ex-dividend date
2026-ж., 29-июн.
P/E ratio
15,47
52-wk high
2 912 JP¥
52-wk low
2 109 JP¥
EPS
164 JP¥
Shares outstanding
547,44 млн
No. of employees
5 миң
Open
2 524 JP¥
High
2 574 JP¥
Low
2 516 JP¥
Mkt. cap
1,34 трлн
Avg. vol.
1,81 млн
Volume
1,13 млн
Dividend
2,63%
Quarterly dividend
17 JP¥
Ex-dividend date
2026-ж., 29-июн.
P/E ratio
15,47
52-wk high
2 912 JP¥
52-wk low
2 109 JP¥
EPS
164 JP¥
Shares outstanding
547,44 млн
No. of employees
5 миң
News stories
From web sources and news partners
Profile
Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and was among the 40 largest in the world by revenue in 2012. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Wikipedia
About Kyowa Kirin Co Ltd
CEOMasashi Miyamoto
Employees5,16 миң
Founded1949-ж., 1-июл.
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Last report
2026-ж., 2-ноя.
Fiscal period
Q3 2026
- / -
Revenue / Est. (JPY)
121,32 млд / 123,80 млд
-2,00%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
147,38 млд
118,47 млд
145,16 млд
121,32 млд
Cost of goods sold
37,87 млд
30,22 млд
36,13 млд
30,24 млд
Cost of revenue
37,87 млд
30,22 млд
36,13 млд
30,24 млд
Research and development expenses
24,35 млд
27,16 млд
19,16 млд
21,37 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31,35 млд
41,07 млд
43,74 млд
38,91 млд
Operating expense
72,15 млд
71,01 млд
94,49 млд
64,67 млд
Total operating expenses
110,02 млд
101,23 млд
130,62 млд
94,90 млд
Operating income
37,35 млд
17,23 млд
14,55 млд
26,41 млд
Other non operating income
13,50 млд
-7,71 млд
7,71 млд
-1,00 млн
EBT including unusual items
39,30 млд
13,93 млд
23,54 млд
27,26 млд
EBT excluding unusual items
51,23 млд
13,93 млд
23,54 млд
27,26 млд
Income tax expense
4,86 млд
1,89 млд
4,96 млд
6,21 млд
Effective tax rate
12,36%
13,59%
21,05%
22,77%
Other operating expenses
3,92 млд
-
28,59 млд
1,35 млд
Net income
34,44 млд
12,03 млд
18,58 млд
21,06 млд
Net profit margin
23,37%
10,16%
12,80%
17,36%
Earnings per share
-
-
-
-
Interest and investment income
2,71 млд
5,68 млд
1,58 млд
977,00 млн
Interest expense
-28,00 млн
-2,27 млд
-
-92,00 млн
Net interest expenses
2,68 млд
3,41 млд
1,58 млд
885,00 млн
Depreciation and amortization charges
12,54 млд
-
-2,78 млд
3,04 млд
EBITDA
44,74 млд
24,88 млд
22,32 млд
34,07 млд
Gain or loss from assets sale
2,77 млд
-
5,56 млд
972,00 млн
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору